SCHEMBL7120048

SCHEMBL7120048

Cc1ccccc1CC(=O)N(C)C

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CTBP2 P56545 1/20 0.51
▸ MEN1 O00255 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ SHBG P04278 1/20 0.45
▸ HPGD P15428 2/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ BCHE P06276 1/20 0.42
▸ ACHE P22303 1/20 0.42
▸ CASP3 P42574 1/20 0.42
▸ CASP7 P55210 1/20 0.42
▸ TSHR P16473 1/20 0.41
▸ POLQ O75417 1/20 0.41
▸ MAPK8 P45983 1/20 0.41
▸ TAAR1 Q96RJ0 1/20 0.41
▸ HTT P42858 1/20 0.40
▸ TRPM8 Q7Z2W7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9890713 0.85 FFAR1 (0.42) CTBP2HPGDALDH1A1BCHEACHE
SCHEMBL24802429 0.83 ALDH1A1 (0.45) CTBP2MEN1MAPTKMT2AHPGD
SCHEMBL11327583 0.82 TAAR1 (0.48) KMT2AHPGDALDH1A1NPC1TSHR
SCHEMBL706704 0.82 CTBP2 (0.46) CTBP2MEN1MAPTKMT2ASHBG
SCHEMBL31443047 0.82 TRPM8 (0.46) CTBP2MEN1MAPTKMT2ASHBG
SCHEMBL28783607 0.81 TAAR1 (0.47) CTBP2MEN1KMT2AHPGDALDH1A1
SCHEMBL1956074 0.80 AKR1B1 (0.61) TSHRPOLQTAAR1
SCHEMBL8902169 0.79 CTBP2 (0.47) CTBP2MEN1MAPTKMT2ASHBG
SCHEMBL2408117 0.79 KMT2A (0.52) CTBP2MAPTKMT2AALDH1A1NPC1
SCHEMBL24802445 0.79 TSHR (0.49) MEN1MAPTKMT2AALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030032803-A1 Novel amide derivatives as inhibitors of matrix metalloproteinases, TNF-alpha, and aggrecanase DUAN JINGWU (US) 2003-02-13 — — US claimed
US-5846990-A Substituted biphenyl isoxazole sulfonamides BRISTOL-MYERS SQUIBB CO. (US) 1998-12-08 — — US claimed
EP-1165500-A1 AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES,TNF-ALPHA,AND AGGRECANASE Du Pont Pharmaceuticals Company (US) 2002-01-02 — — EP disclosed
WO-2000059874-A1 NOVEL AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE DU PONT PHARMACEUTICALS COMPANY (US) 2000-10-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030032803-A1 Novel amide derivatives as inhibitors of matrix metalloproteinases, TNF-alpha, and aggrecanase TNF, MMP1, ADAMTS1 CTBP2 4534/4885MEN1 3003/4885MAPT 2281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback